About NGL Fine Chem Ltd
NGL Fine-Chem operates at the intersection of pharmaceutical science manufacturing precision and healthcare reliability. Serving both animal and human health markets, the Company manufactures and exports Active Pharmaceutical Ingredients (APIs), advanced intermediates and finished dosage forms, across global markets. Over the last four decades, NGL has evolved from being a strong domestic manufacturer into a globally trusted partner known for process expertise, dependable supply and consistent quality.
Founded
1981
CEO
Dhananjay N Mungale
Employees
502
HQ
Mumbai, India
Finished Products
1Sale of Products
₹1,160.70Cr2Other Operating Revenues
₹16.34CrRaw Materials
1Raw material consumed
₹166.58Cr2Packing Material
₹2.47CrAbout NGL Fine Chem Ltd
NGL Fine-Chem operates at the intersection of pharmaceutical science manufacturing precision and healthcare reliability. Serving both animal and human health markets, the Company manufactures and exports Active Pharmaceutical Ingredients (APIs), advanced intermediates and finished dosage forms, across global markets. Over the last four decades, NGL has evolved from being a strong domestic manufacturer into a globally trusted partner known for process expertise, dependable supply and consistent quality.
Founded:1981
CEO:Dhananjay N Mungale
Employees:502
HQ:Mumbai, India
Finished Products
1Sale of Products
₹1,160.70Cr2Other Operating Revenues
₹16.34CrRaw Materials
1Raw material consumed
₹166.58Cr2Packing Material
₹2.47CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹3,602
52W Low
₹1,271
Volume11.22K
Avg VolumeN/A
Beta1.33
Dividend Yield0.07%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
29.05x
Valuation
P/B Ratio
5.05x
Valuation
EPS
₹92.56
Valuation
Dividend Yield
0.07%
Valuation
ROE
14.62%
Profitability
ROCE
15.37%
Profitability
Revenue by Segment
Contribution & growth by business line
PharmaceuticalsRevenue split N/A
Geographical Revenue Split
Domestic vs international exposure
Domestic
25.9%
International
74.1%
Asia Pacific31.1%
Rest of the world29.6%
India25.9%
Europe12.1%
USA1.3%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.33x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
13.9%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.